For income investors watching volatile market conditions, the comfort of a regular, reliable dividend is hard to overstate. But finding these kinds of shares isn't easy... Excessive yields, weak financials and variable payouts can all...
BMY — Bristol-Myers Squibb Co Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedLarge CapSuper Stock
- $161.72bn
- $191.79bn
- $46.39bn
- 96
- 53
- 90
- 91
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.74 | ||
| PEG Ratio (f) | 0.3 | ||
| EPS Growth (f) | 48.34% | ||
| Dividend Yield (f) | 2.86% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.12 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 10.68 | ||
| Price to Sales | 3.44 | ||
| EV to EBITDA | 9.83 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.1% | ||
| Return on Equity | 18.07% | ||
| Operating Margin | 18.97% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 20,776 | 22,561 | 26,145 | 42,518 | 46,385 | 46,461.06 | 48,363.28 | 19.01% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +27.11 | +24.51 | -31.77 | n/a | n/a | +99.07 | +7.38 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for BMY
Shares in Bristol-myers Squibb Co (NYQ:BMY) are currently trading at 60.01 but the question for investors is how much the market chaos of 2020 will impact on its price. The answer comes down to judging whether Bristol-myers Squibb Co i...
The Bristol-myers Squibb Co (NYQ:BMY) share price is currently trading at 63.27. But to try and predict what the price will look like in the next 12 months and beyond, it's worth knowing its strengths and potential weaknesses. The good...
Profile Summary
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
Directors
- Giovanni Caforio CHM (56)
- David Elkins CFO (52)
- Ann Powell CHO (55)
- Sandra Leung EVP (60)
- Christopher Boerner EVP (50)
- Samit Hirawat EVP (52)
- Elizabeth Mily EVP (53)
- Louis Schmukler EVP (65)
- Rupert Vessey EVP (56)
- Paul von Autenried SVP (59)
- Adam Dubow SVP (54)
- Karen Santiago SVP (50)
- Joseph Eid SVP (53)
- Theodore Samuels LED (66)
- Manuel Medina DRC (53)
- Peter Arduini IND (56)
- Julia Haller IND (66)
- Paula Price IND (60)
- Derica Rice IND (56)
- Gerald Storch IND (64)
- Karen Vousden IND (63)
- Phyllis Yale IND (63)
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- August 11th, 1933
- Public Since
- July 5th, 1929
- No. of Shareholders
- 34,417
- No. of Employees
- 32,200
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 2,129,064,271
- Address
- 430 E 29th St Fl 14, NEW YORK, 10016-8367
- Web
- https://www.bms.com/
- Phone
- +1 2125464000
- Auditors
- Deloitte & Touche LLP
Latest News for BMY
Upcoming Events for BMY
Q2 2022 Bristol-Myers Squibb Co Earnings Call
Q2 2022 Bristol-Myers Squibb Co Earnings Release
Q3 2022 Bristol-Myers Squibb Co Earnings Call
Q3 2022 Bristol-Myers Squibb Co Earnings Release
Similar to BMY
Abbvie
New York Stock Exchange
Amneal Pharmaceuticals
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Catalent
New York Stock Exchange
FAQ
What is the Bristol-Myers Squibb Co share price?
As of Today at 07:04 UTC, shares in Bristol-Myers Squibb Co are trading at $75.96. This share price information is delayed by 15 minutes.
How has the Bristol-Myers Squibb Co share price performed this year?
Shares in Bristol-Myers Squibb Co last closed at $75.96 and the price had moved by +15.88% over the past 365 days. In terms of relative price strength the Bristol-Myers Squibb Co share price has outperformed the S&P500 Index by +23.56% over the past year.
What are the analyst and broker recommendations for Bristol-Myers Squibb Co?
The overall consensus recommendation for Bristol-Myers Squibb Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Bristol-Myers Squibb Co dividend yield?
The Bristol-Myers Squibb Co dividend yield is 2.65% based on the trailing twelve month period.
Does Bristol-Myers Squibb Co pay a dividend?
Last year, Bristol-Myers Squibb Co paid a total dividend of $2.01, and it currently has a trailing dividend yield of 2.65%. We do not have any data on when Bristol-Myers Squibb Co is to next pay dividends.
When does Bristol-Myers Squibb Co next pay dividends?
We do not have data on when Bristol-Myers Squibb Co is to next pay dividends. The historic dividend yield on Bristol-Myers Squibb Co shares is currently 2.65%.
How do I buy Bristol-Myers Squibb Co shares?
To buy shares in Bristol-Myers Squibb Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bristol-Myers Squibb Co?
As of the previous close price of $75.96, shares in Bristol-Myers Squibb Co had a market capitalisation of $161.72bn.
Where are Bristol-Myers Squibb Co shares listed?
Here are the trading details for Bristol-Myers Squibb Co:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: BMY
What kind of share is Bristol-Myers Squibb Co?
Based on an overall assessment of its quality, value and momentum Bristol-Myers Squibb Co is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bristol-Myers Squibb Co share price forecast for 2022?
The analyst consensus target price for shares in Bristol-Myers Squibb Co is $79.40. That is 4.53% above the last closing price of $75.96.
Analysts covering Bristol-Myers Squibb Co currently have a consensus Earnings Per Share (EPS) forecast of $7.59 for the next financial year.
What is the trend in the Bristol-Myers Squibb Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bristol-Myers Squibb Co. Over the past six months, its share price has outperformed the S&P500 Index by +57.69%.
As of the last closing price of $75.96, shares in Bristol-Myers Squibb Co were trading +15.94% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bristol-Myers Squibb Co PE Ratio?
The Bristol-Myers Squibb Co PE ratio based on its reported earnings over the past 12 months is 9.74. The shares last closed at $75.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bristol-Myers Squibb Co?
Bristol-Myers Squibb Co's management team is headed by:
- Giovanni Caforio - CHM
- David Elkins - CFO
- Ann Powell - CHO
- Sandra Leung - EVP
- Christopher Boerner - EVP
- Samit Hirawat - EVP
- Elizabeth Mily - EVP
- Louis Schmukler - EVP
- Rupert Vessey - EVP
- Paul von Autenried - SVP
- Adam Dubow - SVP
- Karen Santiago - SVP
- Joseph Eid - SVP
- Theodore Samuels - LED
- Manuel Medina - DRC
- Peter Arduini - IND
- Julia Haller - IND
- Paula Price - IND
- Derica Rice - IND
- Gerald Storch - IND
- Karen Vousden - IND
- Phyllis Yale - IND